113 related articles for article (PubMed ID: 12876530)
1. [Diagnostic management of inaugurable metastases].
Penel N
Presse Med; 2003 Jun; 32(21):990-6, 1004. PubMed ID: 12876530
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary.
Nguyen TT; Kreisel FH; Frater JL; Bartlett NL
J Clin Oncol; 2013 Nov; 31(33):e443-5. PubMed ID: 23775969
[No Abstract] [Full Text] [Related]
3. Diagnostic and therapeutic management of cancer of an unknown primary.
Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma of unknown primary (CUP).
Pavlidis N; Fizazi K
Crit Rev Oncol Hematol; 2009 Mar; 69(3):271-8. PubMed ID: 18977667
[TBL] [Abstract][Full Text] [Related]
5. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.
DeYoung BR; Wick MR
Semin Diagn Pathol; 2000 Aug; 17(3):184-93. PubMed ID: 10968704
[TBL] [Abstract][Full Text] [Related]
6. [Prognosis and possibilities of treatment of inaugural metastases].
Penel N
Presse Med; 2003 Jun; 32(21):997-1004. PubMed ID: 12876531
[TBL] [Abstract][Full Text] [Related]
7. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
[TBL] [Abstract][Full Text] [Related]
8. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
9. Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site.
Kandalaft PL; Gown AM
Arch Pathol Lab Med; 2016 Jun; 140(6):508-23. PubMed ID: 26457625
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical identification of carcinomas of unknown primary in serous effusions.
Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A
Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395
[TBL] [Abstract][Full Text] [Related]
11. Status of External Quality Assessment on Tumor Markers in China.
Xiao Y; Zhang C; Zhao H; Wang W; He F; Zhong K; Yuan S; Wang Z
Clin Lab; 2015; 61(10):1383-90. PubMed ID: 26642698
[TBL] [Abstract][Full Text] [Related]
12. [Peritoneal carcinomatosis of unknown origin].
Marchal N; Gennigens C; Jerusalem G
Rev Med Liege; 2012 Nov; 67(11):582-6. PubMed ID: 23346828
[TBL] [Abstract][Full Text] [Related]
13. Use of common seric tumor markers in patients with solid cancers.
Gara S; Boussen H; Ghanem A; Guemira F
Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
[TBL] [Abstract][Full Text] [Related]
14. CUP: looking for a missing primary site and its biology.
Pentheroudakis G
Ann Oncol; 2012 Sep; 23 Suppl 10():x278-81. PubMed ID: 22987976
[No Abstract] [Full Text] [Related]
15. Immunocytochemical evaluation of primary human esophageal carcinomas and their xenografts for keratin, beta-chorionic gonadotropin, placental lactogen, alpha-fetoprotein, carcinoembryonic antigen, and nonspecific cross-reacting antigen.
Burg-Kurland CL; Purnell DM; Combs JW; Valerio MG; Harris CC; Trump BF
Cancer Res; 1986 Nov; 46(11):5730-7. PubMed ID: 2428482
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
[TBL] [Abstract][Full Text] [Related]
17. Management of peritoneal carcinomatosis of unknown primary tumor site.
Muggia FM; Baranda J
Semin Oncol; 1993 Jun; 20(3):268-72. PubMed ID: 8503022
[No Abstract] [Full Text] [Related]
18. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Greco FA
Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT.
Keller F; Psychogios G; Linke R; Lell M; Kuwert T; Iro H; Zenk J
Head Neck; 2011 Nov; 33(11):1569-75. PubMed ID: 21990221
[TBL] [Abstract][Full Text] [Related]
20. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
